Skip to main content

Table 3 Demographic data of clinical cases, diagnoses and pathologic findings

From: Tau Ser208 phosphorylation promotes aggregation and reveals neuropathologic diversity in Alzheimer’s disease and other tauopathies

 AgeGenderPrimary DiagnosisSecondary DiagnosisThal Phase (A score)Braak stage (B score)CERAD (C score)
AD78femaleADNC, highCAA4 (A3)VI (B3)frequent (C3)
AD64femaleADNC, highCAA4 (A3)VI (B3)frequent (C3)
AD77maleADNC, highARTAG; CAA4 (A3)VI (B3)moderate (C2)
AD64maleADNC, highCAA5 (A3)VI (B3)frequent (C3)
AD68maleLBD (neocortical)ADNC, intermediate3 (A2)V (B3)frequent (C3)
DLB81femaleADNC, highLBD (neocortical); CAA4 (A3)VI (B3)frequent (C3)
DLB68femaleLBD (neocortical)ADNC, high; CAA; LATE stage15 (A3)V (B3)frequent (C3)
DLB83maleADNC, intermediateLBD (neocortical); CAA; LATE stage 23 (A2)V (B3)frequent (C3)
PSP63femaleFTLD-tau (PSP) 0 (A0)0 (B0)none (C0)
PSP69femaleFTLD-tau (PSP)ADNC, low3 (A2)III (B2)none (C0)
PSP72femaleFTLD-tau (PSP)PART (Braak II)0 (A0)II (B1)none (C0)
PSP78maleFTLD-tau (PSP) 0 (A0)0 (B0)none (C0)
PSP77maleFTLD-tau (PSP)ADNC, low; CAA2 (A1)II (B1)none (C0)
CBD73femaleFTLD-tau (CBD)ADNC, low; CAA1 (A1)II (B1)none (C0)
CBD70maleFTLD-tau (CBD)ADNC, low; CAA3 (A2)II (B1)none (C0)
  1. Primary neuropathologic diagnoses were based on current guidelines for Alzheimer’s disease neuropathologic change (ADNC) [59], dementia with Lewy Bodies (DLB) [55], and frontotemporal lobar dementia-tau (FTLD-tau) pathology [52], including progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD) [20]. Additionally, secondary neuropathologic changes were determined following guidelines for cerebral amyloid angiopathy (CAA) [13], Aging-related tau astrogliopathy (ARTAG) [48], and limbic-predominant age-related TDP-43 encephalopathy (LATE) [64]